AI Article Synopsis
- * Dysregulation of SET is connected to worse patient outcomes and resistance to treatments, making it a focus for new cancer therapies.
- * The review will cover SET's functions, its inhibitors, and the potential challenges in developing these inhibitors into effective cancer treatments.
Article Abstract
SET protein is a multi-functional oncoprotein that is ubiquitously expressed in most tumor cells. Dysregulation of SET has been associated with many types of cancer. Due to ever-accumulating evidence of its strong correlation with both poor prognosis and drug resistance, the targeting of SET is starting to be explored. SET is currently regarded as a potential target for cancer therapy, and several inhibitors are being developed for clinical trials. In this review, the physiological and pathological functions of SET, as well as its antagonists, will be discussed along with the prospects and challenges involved with translating SET inhibitors into bona fide therapeutic options.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1389557521666210114163318 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!